Seres Therapeutics (MCRB) Misses Q4 EPS by 61c
Tweet
Share
E-mailGet Alerts MCRB Hot Sheet
Join SI Premium – FREE
Seres Therapeutics (NASDAQ: MCRB) reported Q4 EPS of ($0.81), $0.61 worse than the analyst estimate of ($0.20).
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Sigma Lithium resumes full operations after signing TAC agreement
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
